DeepMed Research

RUTGERS, THE STATE UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

The Effects of Epinephrine in Endotoxemia in Normal Volunteers

Phase 1

Completed

Conditions: Immune System

Interventions: Biological: Endotoxin, Lipopolysaccharide, LPS
Biological: Endotoxin, Epinephrine

First Posted Date: 2008-09-16

Last Posted Date: 2015-05-27

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 37

Registration Number: NCT00753402

Locations: 🇺🇸
Rutgers-RWJMS, New Brunswick, New Jersey, United States

Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: hydroxychloroquine

First Posted Date: 2008-08-01

Last Posted Date: 2022-06-16

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 64

Registration Number: NCT00726596

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Carol G. Simon Cancer Center at Morristown Memorial Hospital, Morristown, New Jersey, United States
🇺🇸
Cancer Institute of New Jersey at Hamilton, Hamilton, New Jersey, United States

and more 2 locations

Propofol Concentration In The Ambient Air Of The Operating Room And In The Blood Of Anesthesia Care Providers

Completed

Conditions: Propofol Pollution

First Posted Date: 2008-06-12

Last Posted Date: 2013-12-11

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 20

Registration Number: NCT00695799

Locations: 🇺🇸
UMDNJ, Newark, New Jersey, United States

Effects of Nitrous Oxide on Intraocular Pressure

Terminated

Conditions: Post Operative Visual Loss

First Posted Date: 2008-06-12

Last Posted Date: 2015-04-24

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 30

Registration Number: NCT00696189

Locations: 🇺🇸
UMDNJ, Newark, New Jersey, United States

Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer

Phase 1

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Sorafenib
Drug: Letrozole

First Posted Date: 2008-03-13

Last Posted Date: 2023-11-09

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 52

Registration Number: NCT00634634

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Cooper Hospital/University Medical Center, Voorhees, New Jersey, United States

and more 1 locations

A Phase I/II Trial of 2-Deoxyglucose (2DG) for the Treatment of Advanced Cancer and Hormone Refractory Prostate Cancer

Phase 1

Terminated

Conditions: Prostate Cancer

Interventions: Drug: 2-deoxyglucose

First Posted Date: 2008-03-11

Last Posted Date: 2023-12-22

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 12

Registration Number: NCT00633087

Locations: 🇺🇸
The Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Doxil
Drug: Carboplatin
Drug: Bevacizumab

First Posted Date: 2008-02-06

Last Posted Date: 2023-02-08

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 31

Registration Number: NCT00608972

Locations: 🇺🇸
Saint Peter's University Hospital, New Brunswick, New Jersey, United States
🇺🇸
Jersey Shore University Medical Center, Neptune, New Jersey, United States
🇺🇸
Cooper Hospital/University Medical Center, Camden, New Jersey, United States

and more 4 locations

Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer

Phase 1

Conditions: Breast Cancer
Colorectal Cancer
Gastric Cancer
Liver Cancer
Melanoma (Skin)
Metastatic Cancer
Ovarian Cancer
Pancreatic Cancer

Interventions: Drug: cyclophosphamide
Drug: poly ICLC
Procedure: hepatic artery embolization
Radiation: 3-dimensional conformal radiation therapy

First Posted Date: 2007-11-04

Last Posted Date: 2014-01-14

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 50

Registration Number: NCT00553683

Locations: 🇺🇸
Rutgrers University Hospital, Newark, New Jersey, United States

Predictors of Treatment Outcome for Smokers With and Without Schizophrenia

Completed

Conditions: Tobacco Dependence

First Posted Date: 2007-07-13

Last Posted Date: 2017-07-17

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 203

Registration Number: NCT00501007

Locations: 🇺🇸
UMDNJ Tobacco Dependence Clinic, New Brunswick, New Jersey, United States

Enhancing Motivation To Quit Smoking In Smokers With Serious Mental Illness

Phase 1

Completed

Conditions: Schizophrenia
Schizoaffective Disorder

Interventions: Behavioral: Motivational Interviewing
Behavioral: Psychoeducation

First Posted Date: 2007-07-13

Last Posted Date: 2017-07-18

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 98

Registration Number: NCT00500695

Locations: 🇺🇸
UMDNJ- Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy